Research Article

Assessment of Therapeutic Benefit and Option Strategy on Intravesical Instillation for Preventing Bladder Cancer Recurrence after Radical Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma

Bo Fan,1 Qiliang Teng,1 Min Sun,2 Yingzi Wang,3 Yutong Wang,4 Zhe Lin,5 Yuchao Wang,6 Xu Duan,4 Liren Zhang,1 Tingyu Chen,6 Sishan Chen,7 Yu Tai,7 Ce Zhang,8 Xishuang Song,9 and Zhiyu Liu1

1Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China
2Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442099, China
3Department of International Medical, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China
4First Clinical College, Dalian Medical University, Dalian 116000, China
5Ethics Committee, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China
6Second Clinical College, Dalian Medical University, Dalian 116000, China
7Department of Anesthesia, Dalian Medical University, Dalian 116000, China
8Director of the Development Planning and Quality Management Department, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China
9Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

Correspondence should be addressed to Ce Zhang; zhangce@dmu.edu.cn, Xishuang Song; song_xishuang@sina.com, and Zhiyu Liu; lzydoct@163.com

Received 8 January 2022; Revised 26 April 2022; Accepted 30 April 2022; Published 30 May 2022

Academic Editor: Jie Mei

Objective. Upper urinary tract urothelial carcinoma (UUT-UC) is a very aggressive disease, characterized by 22%–50% of patients suffering from subsequent bladder recurrence after radical nephroureterectomy (RNU). Although the therapy of intravesical instillation is reported to be effective in preventing bladder recurrence, no study had been reported in Northeast China. The findings relating to the clinical effectiveness of intravesical instillation after RNU are somewhat controversial, and the best efficacy and least adverse effects of instillation drugs have not been widely accepted. Here, we aimed at evaluating the efficacy of intravesical instillation for the prevention of intravesical recurrence systematically.

Methods. In this retrospective cohort study, from October 2006 to September 2017, 158 UUT-UC patients underwent RNU were divided into 4 groups: epirubicin (EPB) instillation group, hydroxycamptothecin (HCPT) instillation group, bacillus Calmette–Guerin (BCG) instillation group, and noninstillation group. Cox univariate and multivariate analyses were employed to identify the risk factors for intravesical recurrence-free survival (IVRFS). The nomogram model was also applied to predict patient outcomes. Subsequently, to evaluate the clinical significance of intravesical instillation comprehensively, several databases including PubMed, Ovid, and Embase were searched and data from published studies with our results were combined by direct meta-analysis. Moreover, a network meta-analysis comparing instillation therapies was conducted to evaluate the clinical efficacy of different instillation drugs.

Results. In our retrospective cohort study, the Kaplan–Meier survival curve demonstrated no significant differences in noninstillation groups were associated with worsened IVRFS. Meanwhile, multivariate analysis indicated that intravesical instillation was independent protective factors for IVRFS (hazard ratio [HR] = 0.731). Moreover, calibration plots, receiver operating characteristic (ROC) curves, area under the curve (AUC) values, and the C-index showed the priority of nomogram’s predictive accuracy. Next, direct meta-analysis including 19 studies showed that intravesical instillation could prevent the recurrence of bladder cancer with a pooled risk ratio (RR) estimate of 0.53. Subgroup analysis by study type, year of intravesical recurrence, first instillation time, and instillation times also confirmed the robustness of the results. Moreover, intraoperative instillation was associated with a decrease in the risk of bladder recurrence compared with
postoperative instillation. Then, a network meta-analysis including 7 studies indicated that pirarubicin (THP) (surface under the cumulative ranking curve [SUCRA] = 89.2%) is the most effective therapy to reduce the risk of bladder recurrence, followed by BCG (SUCRA = 83.5%), mitomycin C (MMC) (SUCRA = 53.6%), EPB (SUCRA = 52.6%), and HCPT (SUCRA = 51.1%) after the analysis of the value ranking. Conclusions. A maintenance schedule of intravesical instillation prevents the recurrence of bladder cancer after RNU in UUT-UC patients effectively. Large, prospective trials are needed to further confirm its value. Compared with other chemotherapy regimens, THP may be a promising drug with favorable efficacy to prevent bladder recurrence. As included studies had moderate risk of bias, the results of network meta-analysis should be applied with caution.

1. Introduction

Upper urinary tract urothelial carcinoma is a rare, latent fatal disease that accounts for nearly 5% of urothelial and 10% of renal tumors [1–4]. Currently, radical nephroureterectomy with bladder cuff removal is the standard treatment [3, 5–8]. Surgery alone can provide sufficient locoregional control only for patients with disease of early stage; however, the overall 5-year survival rate for patients with locally advanced urothelial carcinoma of the renal pelvis and ureter is 0% to 34% after surgery [9–12]. Moreover, urothelial cancer tumors are formed synchronously and/or metachronously in multiple foci throughout the whole urinary tract, which is one of the most essential characteristics of urothelial cancer. Previous studies have indicated that 22–50% of patients undergoing surgical treatment for UUT-UC develop subsequent urinary bladder recurrence [3, 6, 13–20].

Although intravesical instillation is a well-established treatment for preventing intravesical recurrence after the transurethral resection of superficial bladder tumors, there is no consensus on the preventive ability of intravesical instillation to inhibit bladder recurrence after RNU for UUT-UC [15, 18, 21–23]. In 2020, a survey was investigated to explore the use of intravesical instillation in daily practice among European colleagues. Surprisingly, less than half (47%) delivered intravesical instillation after RNU regularly, and 35% ignored the evidence [24]. This may be explained by the limited relevant studies and inconsistent conclusions. O’Brien T et al. demonstrated that the intravesical instillation of MMC could reduce the bladder recurrence rate significantly following nephroureterectomy for UUT-UC [18], which is similar to a randomized controlled trial (RCT) study performed by Ito A et al. in Japan [23]. However, no statistically significant difference was noticed in the rates of bladder recurrence among different intravesical instillation groups and the control group in the studies of Wu et al. [15] and Sakamoto et al. [21]. Therefore, in this study, we first determined the clinical significance of intravesical instillation in a retrospective cohort enrolling 158 UUT-UC patients to predict intravesical recurrence-free survival. Then, to comprehensively evaluate the efficacy of intravesical instillation for the prevention of intravesical recurrence after RNU, we performed a meta-analysis with relevant, eligible published research studies on the basis of searching electronic journals. Meanwhile, we conducted subgroup analyses according to the study type, time of the first instillation, instillation times, and yearly recurrence probability to further verify our findings.

Despite this, we also cannot judge which chemotherapy drug and instillation strategies are the most effective. The ODMIT-C trial demonstrated that the intravesical instillation of MMC could reduce the bladder recurrence rate significantly [18]. A prospective randomized phase II study in Japan suggested that the intravesical instillation of THP appears to be effective for preventing bladder recurrence [23]. Another study suggested that no statistically significant difference was found in the bladder recurrence rates among the MMC group, EPB group, and control group [15]. Since network meta-analyses are used to analyze multiple therapies synchronously by integrating direct and indirect evidence, we then conducted network meta-analyses to assess the comparable effectiveness of various instillation regimens.

2. Materials and Methods

2.1. Retrospective Cohort Study

2.1.1. Patient Assessment. We retrospectively collected the clinical data of patients diagnosed with UUT-UC who underwent RNU with bladder cuff removal at the Second Hospital of Dalian Medical University from October 2006 to September 2017. The inclusion criteria were as follows: (i) patients pathologically diagnosed with primary UUT-UC without the history of bladder cancer; (ii) patients underwent RNU; and (iii) patients had full clinical record and follow-up data. The exclusion criteria are as follows: (i) patients with concomitant bladder cancer or had a previous history of bladder cancer; (ii) patients diagnosed with metastatic systemic disease such as bone metastases, lung metastases, and liver metastases; and (iii) patients receiving neoadjuvant radiotherapy or chemotherapy, systemic chemotherapy, and endoscopic treatments. Clinical information on demographic characteristics, relevant inspection results, and follow-up records was collected. The selection of instillation drugs, including BCG, EPB, and HCPT, mainly depended on the description of the cost of therapy, adverse events during treatment, the voluntary nature of the patient, and surgeons’ experience. After excluding patients who stopped intravesical chemotherapy halfway due to adverse events or lost to follow-up, one hundred and fifty-eight patients were retrospectively enrolled in this study cohort. Among them, 41 patients underwent intravesical instillation of 30 mg EPB in 50 ml saline solution after surgery; 33 patients underwent intravesical instillation of 10 mg HCPT in 50 ml saline solution after surgery; 36 patients underwent intravesical instillation of 120 mg BCG in 50 ml saline solution after surgery; and the other patients did not receive...
preventive instillation after RNU. All instillation groups were initiated two weeks after surgery, and the frequency of instillation was once a week. The solution was retained for at least half an hour. In all, a total of 8 instillations were given over a period of 2 months.

2.1.2. Follow-up Regimen. All patients generally underwent cystoscopy, urinalysis, and cytologic examination per 3 months in the first 2 years, per 6 months in the second year, and annually thereafter to screen for recurrence. Chest/abdominal computed tomography (CT) scans and bone scans were conducted when clinically indicated. Recurrence was identified as pathologic confirmation of urinary tract cancer by cystoscopic biopsy or transurethral resection. The primary endpoint was IVRFS, which was measured from surgery to the date at which recurrence was pathologically confirmed.

2.1.3. Statistical Analysis. The clinicopathological factors affecting bladder recurrence were compared by Student's t-test and the χ² test for continuous and categorical variables, respectively. The probabilities of IVRFS were determined by Kaplan–Meier survival analysis, and the log-rank test values were applied to assess the differences of statistical significance. The prognostic effects of clinical variables on recurrence were estimated by univariate and multivariate Cox regression analyses. HRs with 95% confidence intervals (CIs) were used to appraise the strength of the individual variables. Statistical analysis was conducted with SPSS 14.0, and p < 0.05 represented statistical significance.

Afterwards, a nomogram was constructed to predict 1-, 3-, and 5-year IVRFS by including independent prognostic factors using the rms package in R software version 3.5.1. The concordance index (C-index) was used to estimate the predictive efficiency and distinguishing ability of the nomogram, which mainly gauged the differences between the predicted and actual outcomes. A superior prognostic accuracy for the model is demonstrated by a higher C-index. ROC curves were constructed to determine the sensitivity and specificity of the nomogram, similar to the use of the C-index. The calibration curve was used to indicate the calibration between the observed recurrence and nomogram-predicted recurrence. Furthermore, the nonadherence nomogram was verified by bootstrapping validation (1,000 bootstrap resamples) to adjust a relatively corrected C-index.

2.2. Meta-Analysis

2.2.1. Search Strategy. The PubMed, Google Scholar, Embase, Ovid MEDLINE, and Cochrane Library databases were used to search studies published before December 2021. The following relevant keywords were used: “upper urinary tract,” “urothelial carcinoma,” “bladder recurrence,” “intravesical recurrence,” “intravesical irrigation,” “intravesical instillation,” “intravesical chemotherapy,” “renal pelvis,” and “ureter.” Bibliographies of the retrieved articles were also hand-searched to identify other potentially eligible trials. No filters were applied for the date of publication or language. Our study was performed based on the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. The PRISMA checklist is shown in Supplementary Table 1. The study has been registered at the PROSPERO register (https://www.crd.york.ac.uk/PROSPERO, registration number: CRD42021285316). A flow diagram of the literature search is shown in Figure 1.

2.2.2. Inclusion and Exclusion Criteria. Studies were eligible when they satisfied the following criteria: (i) patients with UUT-UC were confirmed after RNU; (ii) the intervention group received intravesical instillation with any kind of chemotherapy or BCG; (iii) the association between intravesical chemotherapy and bladder recurrence was reported; and (iv) the RR or HR for intravesical recurrence-free survival rate after RNU was reported or could be calculated. The following exclusion criteria were used: (i) single-arm studies, case reports, letters to the editor without original data, reviews, or commentaries; (ii) duplicated publications for the same author or institute; (iii) failure to provide information on bladder recurrence after RNU; (iv) based on the given information, absence of information on the HR or RR and its standard error; (v) articles evaluating the recurrence-free survival rates after preoperative; and (vi) articles enrolled the patients who had experienced bladder recurrence.

2.2.3. Data Extraction. A meticulous procedure was conducted independently by three investigators (Bo Fan, Qiliang Teng, and Yingzi Wang), who selected potentially related studies according to the predetermined criteria. Any discrepancies in extracting data were assessed by three reviewers (Zhiyu Liu, Xishuang Song, and Guoyu Wu), who checked the resulting extractions. Data collected from the studies included study type, region, year of publication, number of patients, recruitment period, author, age, sex, tumor characteristics, information of intravesical instillation (regimens, first instillation time, instillation times, treatment duration), and the HR/RR and its 95% CI for intravesical recurrence-free survival. IVRFS was regarded as the interval between RNU and the first intravesical recurrence.

2.2.4. Sensitivity Analysis. The leave-one-out approach was adopted to delete individual trials sequentially. The fixed-effects model was conducted after deleting the studies with heterogeneity if the p value was greater than 0.05 by the Q-test. The random-effects model was conducted when there was heterogeneity observed after removing the individual study.

2.2.5. Statistical Analysis

(1) Direct Meta-analysis. For dichotomous outcomes, the RR with its 95% CI was estimated. The χ² test and the Tau² and I² statistics were calculated to assess heterogeneity, estimate the overall/residual heterogeneity, and evaluate the
inconsistency percentage, respectively. There was no heterogeneity in studies when the \( p \) value was more than 0.1 in the \( \chi^2 \) test. The pooled RRs and corresponding 95% CIs of each study were estimated by fixed-effects models. Otherwise, random-effects models will be conducted. The \( I^2 \) value reflected the proportion of the overall difference that was due to heterogeneity instead of sampling errors. An \( I^2 \) statistic >50% indicated the presence of high heterogeneity; then, the random-effects model will be carried out. Otherwise, the fixed-effects model was used. The \( Z \) test was used to assess the significance of the overall effect, and the funnel plot indicated the potential publication bias. The results were defined as significant statistically with two-sided \( p \) values < 0.05. The direct meta-analysis was conducted by Stata 12.0 (Stata Corporation, College Station, TX, USA).

(2) Network Meta-analysis (NMA). The NMA within a Bayesian framework was performed by synthesizing direct and indirect evidence of intravesical instillation regimens. A net plot was constructed to demonstrate the connection between each intervention and the endpoint [25]. We used the inconsistency factor (IF) to assess the possible sources of inconsistency among trials within direct and indirect effectiveness for the same comparison. IF values with 95% CIs were truncated at zero, indicating no statistically significant deviation [26]. The summary treatment effects on each comparison were estimated as RRs with 95% CIs in a forest plot. In addition, the SUCRA was used to rank the effects of different treatment options [27]. The contribution of each direct comparison to the combined results is shown by a contribution plot [28]. Moreover, we evaluated the deviation in loops of the intravesical instillation network by adopting loop-specific heterogeneity estimates through the method of moments. A comparison-adjusted funnel plot was carried out to assess publication bias. A conclusion of no publication bias was considered when the funnel plots were scattered symmetrically around the zero line [29].

3. Results

3.1. Baseline Patient Characteristics. We analyzed 158 UUT-UC patients including 88 males and 70 females with a median age at diagnosis of 69 years (range from 59 to 80) from October 2006 to September 2017.
clinopathological characteristics of patients are presented in Table 1, and no statistically significant differences were observed between the groups in terms of age, tumor laterality, tumor location, tumor foci, vessel tumor embolus, tumor stage, pathologic grade, lymph node status, perineural invasion, or type of surgery except for sex. The median follow-up time was 29.2 months (range from 2.3 to 122.1). Among 158 patients, 63 subsequently had bladder tumor recurrence during follow-up after nephroureterectomy. The intravesical recurrence rate of the non-instillation group was higher than that of the EPB group, HCPT group, and BCG group (60.4% vs. 24.4%, 57.6%, and 13.9%, respectively).

3.2. The Effectiveness of Intravesical Instillation for Intravesical Recurrence in UUT-UC Patients. Kaplan–Meier survival curves of IVRFS were plotted according to pathological grade, tumor stage, perineural invasion, and intravesical instillation. Lower pathological grade (p = 0.020), non-muscular invasive type (p = 0.004), no perineural invasion (p = 0.023), and instillation group (p < 0.001) achieved a better effect on IVRFS (Figures 2(a)–2(d)). Univariate analysis revealed that intravesical instillation (p = 0.007), tumor stage (p = 0.006), perineural invasion (p = 0.032), and pathological grade (p = 0.023) were significant prognostic factors for IVRFS. Tumor stage (p = 0.016), perineural invasion (p = 0.043), and intravesical instillation (p = 0.015) were defined as independent prognostic indicators for IVRFS in UUT-UC patients by multivariate analysis (Table 2).

The nomogram model for predicting the 1-, 3-, and 5-year IVRFS rates of individual UUT-UC patients was constructed with three independent prognostic indicators in conjunction with age, surgical approach, and pathological grade (Figure 3). Compared with AJCC models, the ROC curves of 1-, 3-, and 5-year IVRFS nomograms revealed better discrimination efficacy. The AUCs of the 1-, 3-, and 5-year IVRFS AJCC models and the nomogram models were equal to 0.588 vs. 0.665, 0.602 vs. 0.690, and 0.627 vs. 0.769, respectively (Figure 4). Good discrimination was also obtained for the bootstrapping method, and the C-index of the nomogram model was equal to 0.704.

The included factors were selected according to multivariate analysis and clinical experience. The nomogram was internally validated. The C-index for IVRFS prediction of the nomograms was 0.737 (95% CI. 0.67–0.801). Furthermore, the relatively corrected C-index of 0.704 was calculated by bootstrapping validation (1,000 bootstrap resamples). Finally, the calibration plots of the nomogram presented a relatively optimal consistency between the actual observations and the predictions (Figure 5).

3.3. Meta-Analysis of the Correlation between Intravesical Instillation and Intravesical Recurrence in UUT-UC Patients. Supplementary Table 2 and Supplementary Table 3 show individual data on characteristics of the included studies and patient population.

3.3.1. Primary Outcome. All 19 trials reported intravesical instillation in UUT-UC patients. Since there was significant heterogeneity overall ($\chi^2 = 62.66; p$ value for heterogeneity < 0.001; $I^2 = 74.5%$), the random-effects model was adopted to measure each study. The pooled results of these trials showed that the use of intravesical instillation lowered the intravesical recurrence rate (RR, 0.53; 95% CI, 0.41–0.70; p < 0.001; Figure 6(a)). As determined by Begg’s test and Egger’s test, the result exhibited a low probability of publication bias (Egger’s test, p = 0.066; Begg’s test, z value = 2.43) (Figure 6(b)). Then, the sequential sensitivity analysis was performed to assess heterogeneity in individual study. By removing any of studies, there was no obvious individual heterogeneity, indicating that the random-effects model with pooled data had moderate reliability. In the leave-one-study-out sensitivity analysis, the complete $I^2$ statistical values and p values by the Q-test are summarized in Figure 7.

3.3.2. Secondary Outcomes

(1) Subgroup Analysis by Study Type. Subgroup analysis was performed by the random-effects model, since significant heterogeneity was found across studies ($\chi^2 = 62.66; p$ value for heterogeneity < 0.001; $I^2 = 74.5%$). The aggregated results demonstrated the incidence of intravesical recurrence in the instillation group was lower than that in the control group in both the retrospective study subgroup (RR, 0.52; 95% CI, 0.38–0.69; p < 0.001) and the prospective study subgroup (RR, 0.61; 95% CI, 0.30–1.27; p = 0.188) (Figure 8(a)). Publication bias was indicated by the funnel plot (Figure 8(b)) and formal statistical analysis (Egger’s test, p < 0.001; Begg’s test, z value = 3.07).

(2) Subgroup Analysis by Year of Intravesical Recurrence. When the seven included studies were pooled in subgroup analyses, the fixed-effects model was carried out, since no heterogeneity was seen ($\chi^2 = 9.02; p$ value for heterogeneity = 0.701; $I^2 = 0.0%$). Compared with the non-ininstallation group, the instillation group was associated with decreases in intravesical recurrence after 1 year (RR, 0.66; 95% CI, 0.49–0.89; p = 0.007), 2 years (RR, 0.69; 95% CI, 0.55–0.88; p = 0.002), and 3 years (RR, 0.65; 95% CI, 0.48–0.88; p = 0.005) (shown in Figure 9(a)). Publication bias was indicated by the funnel plot (Figure 9(b)) and formal statistical analysis (Egger’s test, p = 0.001; Begg’s test, z value = 3.11).

(3) Subgroup Analysis by The First Instillation Time Postoperatively. Nine included studies were pooled in subgroup analyses, and the fixed-effects model was conducted, since no heterogeneity was seen ($\chi^2 = 9.98; p$ value for heterogeneity = 0.442; $I^2 = 0.0%$). The results demonstrated that the risk of intravesical recurrence in the instillation group was significantly lower than that in the control group in the first instillation within 48-h subgroup (RR, 0.50; 95% CI, 0.36–0.69; p < 0.001), the first instillation within 2-week
|                        | EPB | HCPT | BCG | Nonintravesical instillation, no. (%) | Total | \( p \) Value |
|------------------------|-----|------|-----|---------------------------------------|-------|--------------|
| **Gender**             |     |      |     |                                       |       | 0.040        |
| Male                   | 18  | 21   | 23  | 33                                    | 88    |              |
| Female                 | 23  | 12   | 15  | 15                                    | 70    |              |
| **Age, years**         |     |      |     |                                       |       | 0.135        |
| Less than 69           | 21  | 16   | 20  | 26                                    | 76    |              |
| 69 or greater          | 20  | 17   | 23  | 22                                    | 82    |              |
| **Tumor laterality**   |     |      |     |                                       |       | 0.466        |
| Right                  | 26  | 16   | 20  | 23                                    | 84    |              |
| Left                   | 15  | 17   | 17  | 25                                    | 74    |              |
| **Tumor location**     |     |      |     |                                       |       | 0.311        |
| Calix or pelvis        | 13  | 17   | 13  | 19                                    | 62    |              |
| Ureter                 | 26  | 13   | 17  | 25                                    | 81    |              |
| More than 1            | 2   | 3    | 1   | 4                                     | 15    |              |
| **Tumor focality**     |     |      |     |                                       |       | 0.112        |
| Unifocal               | 33  | 29   | 32  | 36                                    | 121   |              |
| Multifocal             | 8   | 4    | 8   | 12                                    | 37    |              |
| **Vessel tumor embolus** |   |      |     |                                       |       | 0.287        |
| Yes                    | 6   | 5    | 5   | 13                                    | 29    |              |
| None                   | 30  | 25   | 29  | 27                                    | 111   |              |
| Unclear                | 5   | 3    | 2   | 8                                     | 18    |              |
| **Tumor stage**        |     |      |     |                                       |       | 0.373        |
| Tis-T1                 | 12  | 6    | 7   | 7                                     | 32    |              |
| T2-T4                  | 29  | 27   | 29  | 41                                    | 126   |              |
| **Pathologic grade**   |     |      |     |                                       |       | 0.152        |
| Low                    | 11  | 13   | 9   | 8                                     | 41    |              |
| High                   | 30  | 20   | 27  | 40                                    | 117   |              |
| **Lymph node status**  |     |      |     |                                       |       | 0.474        |
| No                     | 37  | 32   | 35  | 44                                    | 148   |              |
| N1                     | 4   | 1    | 1   | 4                                     | 10    |              |
| **Perineural invasion**|     |      |     |                                       |       | 0.145        |
| No                     | 40  | 33   | 32  | 44                                    | 149   |              |
| Yes                    | 1   | 0    | 4   | 4                                     | 9     |              |
| **Surgical approach**  |     |      |     |                                       |       | 0.171        |
| Open                   | 15  | 15   | 9   | 12                                    | 51    |              |
| Laparoscopic           | 26  | 18   | 27  | 36                                    | 107   |              |
subgroup (RR, 0.59; 95% CI, 0.47–0.76; \( P < 0.001 \)), and the first instillation after 2-week subgroup (RR, 0.72; 95% CI, 0.58–0.90; \( p < 0.003 \)) (Figure 10(a)). Publication bias was indicated by the funnel plot (Figure 10(b)) and formal statistical tests (Egger’s test, \( p < 0.004 \); Begg’s test, \( z \) value = 2.02).

(4) Subgroup Analysis by the Instillation Times. Twelve included studies were pooled in subgroup analyses, and the fixed-effects model was used, since no heterogeneity was seen (\( \chi^2 = 14.99; \) \( p \) value for heterogeneity = 0.308; \( I^2 = 13.3\% \)). The results suggested that both the single (RR, 0.61; 95% CI, 0.47–0.79; \( p < 0.001 \)) and multiple (RR, 0.61; 95% CI, 0.52–0.72; \( p < 0.001 \)) instillations group were associated with the reduction in the intravesical recurrence rate (Figure 11(a)). Publication bias was indicated by the funnel plot (Figure 11(b)) and formal statistical tests (Egger’s test, \( p < 0.001 \); Begg’s test, \( z \) value = 3.07).

3.4. Meta-Analysis of the Correlation between Intravesical Instillation times and Intravesical Recurrence in UUT-UC Patients. Figure 12 shows two trials reporting data on the efficiency of single or multiple instillations for the prevention of bladder recurrence. Since significant heterogeneity was discovered, the random-effects model was used (\( \chi^2 = 4.84; \) \( p \) value for heterogeneity = 0.028; \( I^2 = 79.4\% \)). For the secondary outcomes, no significant differences were observed between the single-instillation group and the multiple-instillation group (RR, 0.93; 95% CI, 0.26–3.29; \( p = 0.912 \)).
3.5. Meta-Analysis of the Correlation between Intra- or Postoperative Intravesical Instillation and Intravesical Recurrence in UUT-UC Patients. Figure 13 shows two trials reporting data on the efficiency of intra- or postoperative instillation for the preventing of bladder cancer recurrence. The fixed-effects model was conducted, since no heterogeneity was seen ($\chi^2 = 0.35$; $p$ value for heterogeneity = 0.551; $I^2 = 0.0\%$). For the secondary outcomes, the incidence of intravesical recurrence in the intraoperative instillation group was significantly lower than that in the postoperative instillation group (RR, 2.64; 95% CI, 1.20–5.83; $p = 0.016$).

### Points

| Age     | Points |
|---------|--------|
| <69     | 1      |
| ≥69     | 2      |

| Surgical approach | Points |
|-------------------|--------|
| Laparoscope       | 1      |
| Open              | 2      |

| Pathologic grade | Points |
|------------------|--------|
| Low              | 1      |
| High             | 2      |

| Tumor stage | Points |
|-------------|--------|
| T1          | 1      |
| T2          | 2      |

| Perineural invasion | Points |
|---------------------|--------|
| No                  | 1      |
| Yes                 | 2      |

| Intravesical instillation | Points |
|---------------------------|--------|
| BCG                       | 1      |
| HCPT                      | 2      |

| Total Points | Points |
|-------------|--------|
| 1–Year Recurrence | 1–Year Recurrence ROC |
| 3–Year Recurrence  | 3–Year Recurrence ROC |
| 5–Year Recurrence  | 5–Year Recurrence ROC |

**Figure 3:** 1-, 3-, and 5-year intravesical recurrence-free survival (IVRFS)-associated nomogram model. The nomogram of IVRFS was based on six factors and established through Cox regression analysis. Abbreviations: EPB, epirubicin; HCPT, hydroxycamptothecin; BCG, bacillus Calmette–Guerin.

**Figure 4:** The receiver operating characteristic (ROC) curves of 1-, 3-, and 5-year intravesical recurrence-free survival (IVRFS) after nephroureterectomy. The ROC curve of 1-year IVRFS (a). The ROC curve of 3-year IVRFS (b). The ROC curve of 5-year IVRFS (c). The blue lines represent nomogram-predicted IVRFS, and the red lines represent AJCC-predicted IVRFS.
3.6. Bayesian Framework Network Meta-Analysis

3.6.1. Network and Contribution. To analyze the therapeutic effect of different drugs for bladder instillation, an NMA was performed after including nine studies on the EPB instillation group, HCPT instillation group, THP instillation group, MMC instillation group, and BCG instillation group. Among them, EPB instillation was the most studied

Figure 5: Calibration curves for predicting intravesical recurrence-free survival (IVRFS) after nephroureterectomy. The 1-year IVRFS calibration curve (a). The 3-year IVRFS calibration curve (b). The 5-year IVRFS calibration curve (c). The black dotted line refers to the optimal nomogram; circles represent the accuracy of prediction; X demonstrates the bootstrap-revised estimates; and erected lines indicate the 95% confidence intervals (CIs).

Note: Weights are from random effects analysis

Sakamoto N 2001
Wu WJ 2010
Miao M 2009
Kim SH 2020

Study ID
Abe T 2010
Yamashita S 2017
Lai S 2021
Ito A 2013
Katims AB 2021
Jiang G 2017
Liu J 2021
Li YR 2020
Huang Y 2019
Nagashima M 2013
O'Brien T 2011
Huang Y 2019
Long X 2016
Ito A 2013

RR (95% CI) Weight (%)
0.24 (0.06, 0.87) 2.81
0.73 (0.57, 0.94) 8.85
0.53 (0.44, 0.70) 100.00
0.69 (0.19, 2.48) 5.82
0.59 (0.29, 1.16) 5.82
0.60 (0.35, 1.02) 6.92
0.28 (0.09, 0.88) 5.48
0.60 (0.35, 1.02) 6.92
0.67 (0.42, 1.06) 7.44
0.26 (0.07, 0.91) 2.98
0.28 (0.09, 0.88) 5.48
0.83 (0.42, 1.69) 8.58
0.67 (0.42, 1.06) 7.44
0.28 (0.09, 0.88) 5.48
0.67 (0.42, 1.09) 7.55
0.48 (0.31, 0.76) 7.55
1.78 (0.70, 5.33) 3.92
0.64 (0.32, 1.27) 8.12
0.24 (0.06, 0.87) 2.81
0.66 (0.45, 0.97) 8.00
0.79 (0.49, 1.31) 7.87
0.87 (0.50, 1.49) 7.87
0.75 (0.50, 1.12) 7.87
0.67 (0.42, 1.06) 7.44
3.92
7.44
8.00

Overall (I² = 74.5%, p < 0.001) 0.53 (0.41, 0.70) 100.00

Figure 6: Overall meta-analysis for intravesical recurrence. Forest and funnel plots for the effect of intravesical instillation on bladder recurrence (a, b). Every square was displayed as a trial, and the range of every square is proportional to the accuracy of the average treatment effectiveness of the study. The 95% confidence interval (CI) for the treatment effectiveness of each study was indicated by the horizontal line. The center of the block is the mean treatment effectiveness across trials, and the width of the block represents its 95% CI.
Figure 8: Forest and funnel plots of the effect of intravesical instillation on bladder recurrence by subgroup analysis according to the study type (a, b).

3.6.2. Network Comparisons and Ranks. The estimated treatment effect and its 95% CI for all comparisons were determined (Figure 16). Of note, for every comparison with the confidence interval, more studies are needed for more apparent significant results. The results demonstrated an impressive tendency in that the THP and BCG instillation
This study
Long X 2016
Bladder recurrence after 3 year
This study
Sakamoto N 2001
Abe T 2010
Ito A 2013
Nagashima M 2013
Bladder recurrence after 2 year
This study
Sakamoto N 2001
O'Brien T 2011
Ito A 2013
Nagashima M 2013
Long X 2016
Bladder recurrence after 1 year

Overall (I² = 0.0%, p = 0.701)

Subtotal (I² = 19.8%, p = 0.289)
Subtotal (I² = 0.0%, p = 0.563)
Subtotal (I² = 0.0%, p = 0.921)

Figure 9: Forest and funnel plots of the effect of intravesical instillation on bladder recurrence by subgroup analysis according to the timing of recurrence (a, b).

Overall (I² = 13.3%, p = 0.308)
Subtotal (I² = 0.0%, p = 0.601)

Figure 10: Forest and funnel plots of the effect of intravesical instillation on bladder recurrence by subgroup analysis according to the first instillation time (a, b).

Overall (I² = 13.3%, p = 0.308)
Subtotal (I² = 0.0%, p = 0.601)

Figure 11: Forest and funnel plots of the effect of intravesical instillation on bladder recurrence by subgroup analysis according to the instillation times (a, b).
Overall (I-squared = 79.4%, p = 0.028)

| Study ID       | RR (95% CI)  | Weight (%) |
|----------------|--------------|------------|
| Huang Y 2019  | 0.93 (0.26, 3.29) | 55.06      |
| Harraz AM 2019| 1.90 (0.70, 5.13)  | 44.94      |
| Overall (I-squared = 79.4%, p = 0.028) | 0.93 (0.26, 3.29) | 100.00     |

NOTE: Weights are from random effects analysis

Figure 12: Overall meta-analysis for intravesical recurrence. Forest and funnel plots for the effect of single or multiple instillations on bladder recurrence (a, b).

Overall (I-squared = 0.0%, p = 0.551)

| Study ID       | RR (95% CI)  | Weight (%) |
|----------------|--------------|------------|
| Freifeld Y 2020 | 2.64 (1.20, 5.83) | 61.00      |
| Noennig B 2018 | 3.57 (0.99, 12.50) | 39.00      |
| Overall (I-squared = 0.0%, p = 0.551) | 2.64 (1.20, 5.83) | 100.00     |

Figure 13: Overall meta-analysis for intravesical recurrence. Forest and funnel plots of the effect of intra- or postoperative instillation on bladder recurrence (a, b).

Figure 14: Network plot of different treatment comparisons and comparison-adjusted funnel plot of the network meta-analysis (NMA) (a, b). The thickness of lines is correlated with the number of studies, and the extent of dots demonstrates the sample size of patients. The red line indicates the null hypothesis, and there is no difference between the study-specific effect size and the respective comparison-specific pooled effect estimates. Various colors refer to different comparisons. Abbreviations: EPB, epirubicin; HCPT, hydroxycamptothecin; MMC, mitomycin C; THP, pirarubicin; BCG, bacillus Calmette–Guerin; control, no-instillation group.
groups were more favorable in preventing the incidence of intravesical recurrence than the other instillation groups, while HCPT instillation seemed to be less effective than the instillation of other drugs. The six instillation groups’ estimated relative rankings of cumulative probabilities of IVRFS are plotted in Figure 16. The SUCRA value rankings of IVRFS were as follows: THP instillation group (89.2%), BCG instillation group (83.5%), MMC instillation group (53.6%), EPB instillation group (52.6%), and HCPT instillation group (5.1%) (Figure 17). Therefore, THP was a more recommended intravesical treatment in UUT-UC patients after surgery.

3.6.3. Inconsistency Analysis and Publication Bias. Loop-specific sensitivity analysis was performed to assess the consistency of the NMA. This NMA was composed of five triangular loops, including BCG-Control-HCPT (B-C-H), BCG-EPB-HCPT (B-E-H), Control-EPB-HCPT (C-E-H), BCG-Control-EPB (B-C-E), and Control-EPB-MMC (C-E-M).
M). All loops revealed no evidence of significant inconsistency (B-C-H, IF = 1.91, 95% CI, 0.00–4.04; B-E-H, IF = 1.19, 95% CI, 0.00–3.40; C-E-H, IF = 1.01, 95% CI, 0.00–2.41; B-C-E, IF = 0.83, 95% CI, 0.00–2.58; C-E-M, IF = 0.41, 95% CI, 0.00–1.70) (Figure 18). The funnel plot for NMA is shown in Figure 14(b). The enrolled studies were distributed symmetrically, demonstrating that this NMA had no significant publication bias (b).

4. Discussion

Although radical nephroureterectomy with the removal of an ipsilateral bladder cuff is the most widely recognized treatment for UUT-UC, 25% to 69% of postoperative patients suffer from subsequent intravesical recurrence of bladder carcinoma, which is one of the predominant concerns regarding prognosis [30–34]. Some studies have found that positive urine cytology was an independent predictor for tumor recurrence [35], and the proximity of the site of bladder mucosal injury and intravesical recurrence locations confirmed the “tumor seeding” theory [36]. Multifocal tumors appear from dispersed viable cancer cells and are therefore monoclonal, transforming by either intraluminal seeding or intraepithelial migration, particularly during surgery [37]. In our study, of the 158 patients, 63 subsequently had bladder tumors after nephroureterectomy during follow-up, with an intravesical recurrence rate of 39.8%, which favors the theory of monoclonal origin by intraluminal seeding. Interestingly, Huang et al. proposed that dispersed viable intraluminal cancer cells are not totally eliminated by a single instillation of chemotherapy, and multiple instillations were more efficient, which supported the theory of “field change” [38].

The whole urothelium is exposed to a variety of carcinogenic insults that can lead to malignancy and multifocal tumors, subsequently derived from separate clones of transformed cells [37]. Reviewing past studies, some prognostic factors have been investigated to identify UUT-UC patients after surgery if they are at risk of bladder recurrence, and urologists then stratify these risks. Subsequently, urologists will schedule an individual and stringent follow-up regimen according to the identified prognostic factors, including ureteral location, multifocality, and invasive pT stage. Moreover, Pieras et al. reported that UUT-UC patients with a tumor size >4 cm had a higher rate of intravesical recurrence [39]. Recent studies revealed that ureterorenoscopy for UUT-UC patients who underwent RNU did not prevent bladder recurrence, as UUT-UC implantation of the bladder in cancer cells may have caused

Figure 17: Surface under the cumulative ranking curves of treatments among different intravesical chemotherapy regimens.

Figure 18: Inconsistency test. Inconsistency indicates the variations between indirect and direct effects estimated for the same comparison. Abbreviation: IF, inconsistency factor.
arise after ureterorenoscopy, supporting the intraluminal seeding hypothesis [40–42]. At the genetic or molecular biology level, Huang Y et al. confirmed that high expression levels of AIB1 (amplified in breast cancer 1) and EIF5A2 (eukaryotic initiation Factor 5A2) were individual predictive factors for bladder recurrence after RNU, and they thought that this information could help urologists to stratify patients to determine those who would benefit from postoperative intravesical chemotherapy [43]. In our study, multivariate analysis suggested that tumor stage (p = 0.016), perineural invasion (p = 0.043), and intravesical instillation (p = 0.015) were independent prognostic indicators of IVRFS in UUT-UC patients (Table 2).

In this study, we found that intravesical instillation could significantly reduce the bladder recurrence rate of patients who underwent RNU. However, given the few relevant investigations, no consensus has been reached. In a single-institutional study of 320 patients, Long et al. proved that the incidence rates of bladder recurrence were significantly decreased by intravesical chemotherapy [44]. Similarly, in a prospective, randomized trial of 220 patients, O’Brien T et al. suggested that the incidence of bladder recurrence after RNU can be lowered by intravesical chemotherapy [18]. In contrast, Sakamoto et al. did not confirm intravesical chemotherapy as a prognostic factor of bladder recurrence, although a trend was observed [21]. In a long-term retrospective study of 196 patients, Wu et al. also found that the incidence of bladder recurrence was higher in the control group than in the MMC and EPB groups, but there was no significant difference [15]. Hence, on the basis of searching PubMed, Google Scholar, Ovid MEDLINE, Embase, and the Cochrane Library, we combined 19 related studies that compared the difference in bladder recurrence incidence between an instillation group and a noninstillation group and performed a meta-analysis. Our results suggested that the RR was 0.53, and the 95% CI ranged from 0.41 to 0.70, demonstrating that intravesical instillation decreased the risk of bladder recurrence by 47%, with a 95% CI ranging from a decrease of 30% to a decrease of 59%. The earliest meta-analysis about intravesical chemotherapy for the prevention of bladder cancer recurrence after surgery for UUT-UC was published by Fang et al. in 2013 [45]. Two years later, one meta-analysis [46] performing subgroup analysis stratified by study type and another meta-analysis [47] performing subgroup analysis by different starting times and cycles of instillations were published separately, which helped to build a comprehensive and systematic understanding of prophylactic bladder instillation. However, as a study of O’Brien T et al. was included in the above meta-analyses, during data extraction, patients analyzed by intention to treat from patients analyzed per protocol were confused by patients in the instillation group who did not receive it, patients in the control group who receive intravesical chemotherapy and patients who had incomplete submitted data during follow-up [18]. Moreover, a study in which some patients in the intervention group received preoperative intravesical instillation of BCG was included in the meta-analysis by Yuan et al [46]. This may interfere with or influence the quality of their conclusion because of the uncertainty of confounding factors, which may make the results less objective for guiding clinical decisions about drug options.

Although our meta-analysis demonstrated that intravesical instillation can effectively prevent the recurrence of bladder cancer after RNU, the details of the implementation of the instillation regimens are worthy of consideration and discussion. (1). When should clinicians recommend the first intravesical instillation for UUT-UC patients after RNU? In our institution, the recurrence rate of instillation group was 30.9% under the first instillation one month after surgery to prevent the aggravation of bladder spasm, which interfered with the healing of the wound after removal of bladder cuff. As first instillation was started within 48 hours in another study by Ito et al. [23], the incidence of bladder recurrence of the instillation group was reported as 16.9%. After evidence-based analysis, subgroup analysis according to the first instillation time showed that the first instillation within 48 h (RR, 0.50; 95% CI, 0.36–0.69; p < 0.001) subgroup may had better preventive effect on bladder cancer recurrence than the first instillation within or after 2 weeks subgroups (RR, 0.59; 95% CI, 0.47–0.76; p < 0.001; RR, 0.72; 95% CI, 0.58–0.90; p = 0.003), which was consistent with those of the study of Wu et al. [47]. Studies have proposed that intraluminal seeding is an important factor leading to the implantation of cancer cells within 24 hours, which is also the basis for the application of a single dose of intravesical instillation after surgery [48]. Therefore, an earlier first instillation time may be recommended for better prophylactic efficacy in preventing intravesical recurrence. (2). How many courses of intravesical instillation should clinicians recommend to UUT-UC patients? In our study, patients of the instillation group underwent intravesical instillation 8 times weekly after surgery. Hwang EC et al. found that single-dose intravesical chemotherapy instillation postoperatively may reduce the incidence of bladder cancer recurrence (HR, 0.51; 95% CI, 0.32–0.82) [49]. However, a multicenter study performed by O’Brien T et al. conducted a single postoperative intravesical dose of MMC [18]. After including 12 related studies, the subgroup analysis stratified by instillation times were conducted and the result revealed that, compared with the respective control group, both intravesical single instillation (RR, 0.61; 95% CI, 0.47–0.79; p < 0.001) and multiple instillations (RR, 0.61; 95% CI, 0.52–0.72; p < 0.001) had protective role on recurrence of bladder cancer after RNU. A further meta-analysis in our study showed that there was no significant difference about the efficacy of preventing bladder recurrence between multiple instillations group and single-instillation group (RR, 0.93; 95% CI, 0.26–3.29; p = 0.912). A comprehensive literature search showed that single-dose intravesical chemotherapy may lower the risk of bladder cancer recurrence compared to no instillation; however, the effect of single-dose instillation on minor or serious adverse events was uncertain [49]. In the study of early single-dose mitomycin C intravesical instillation after robot-assisted radical nephroureterectomy, patients did not show adverse reactions potentially associated with mitomycin C instillation within 30 days [50]. Conversely, multiple mitomycin C instillation
for high-risk nonmuscle-invasive bladder cancer may lead to adverse events, such as urinary frequency, incontinence, and urinary tract pain [51]. For intravesical multiple BCG instillation, fever, appetite loss, and malaise were the most frequent in the general condition of adverse events [52]. Therefore, single instillation may not only improved quality of life for patients with lower potential adverse events, but also reduced living stress of patients due to reduced financial sharing, compared with multiple instillations. Based on consideration of inherent heterogeneity among intravesical drugs or regimen, large-scale multicenter studies would facilitate the unraveling of the mystery with caution. (3) In addition to postoperative intravesical instillation, would clinicians apply intraoperative intravesical chemotherapy for UUT-UC patients during surgery? After searching electronic databases, a meta-analysis identifying two related studies was conducted, and the results suggested that the intraoperative instillation group was associated with a decrease in the risk of bladder recurrence compared with the postoperative instillation group (RR, 2.64; 95% CI, 1.20–5.83; \( p = 0.016 \)) [53, 54]. Moriarty et al. proposed the safety of intraoperative instillation, which can ensure the earliest and safest delivery method while eliminating the concerns of delaying instillation due to extravasation [55]. Despite the limited number of studies, intraoperative instillation may be an alternative option for patients who cannot tolerate the adverse reactions of postoperative instillation. (4) Which instillation drugs selected by clinicians are most effective for reducing intravesical recurrence? The ODMIT-C trial demonstrated that intravesical instillation of MMC could significantly reduce the incidence of bladder recurrence [18]. A prospective randomized phase II study in Japan suggested that the intravesical instillation of THP appears to be effective [23]. Another study found that no statistically significant differences were observed in the bladder recurrence rates among the MMC group, EPB group, and control group [15]. Since network meta-analyses are used to analyze multiple therapies synchronously by integrating direct and indirect evidence, we combined 9 eligible studies that included 5 different drugs and performed a network meta-analysis. The results demonstrated that the most effective drug was THP (89.2%), followed by BCG (83.5%), according to the SUCRA value rankings of IVRFS. Therefore, BCG combined with THP may be a promising instillation regimen, which warrants further investigation for verification.

Since there is little research on Northeast China, our retrospective cohort study was conducted to investigate intravesical chemotherapy in preventing intravesical recurrence after RNU. However, some limitations affecting the results of this study are listed as follows. As a single-center study, the retrospective nature of different surgical techniques and experiences by multiple surgeons had inherent potential for selection bias. We enrolled patients who were diagnosed between 2006 and 2017. However, the clinical experience, treatment regimen, and surgical skill may change over time, which could impact the outcomes. Furthermore, a relatively small cohort of 158 patients may limit the analysis of more risk factors for intravesical recurrence, such as history of hypertension, history of diabetes, history of cerebrovascular disease, history of smoking, history of drinking, marital status, and others. Thus, conclusions about efficacy should be made with caution. On the other hand, direct meta-analysis and network meta-analysis provide comprehensive insights into instillation regimens, including drug selection, opportunity of instillation, course of instillation, and the first instillation time, and yield the most up-to-date evidence about the value of intravesical instillation in preventing bladder cancer recurrence after RNU. However, most studies were retrospective with their own limitations, such as selection bias. Broad heterogeneity exists in the administration schedules of intravesical instillation, including drug type, dose, and drug retention time, which impedes us from drawing unequivocal conclusions. The small number (less than 5) of several meta-analyses limits the robustness of the results. The evidence extracted from eligible trials was limited in determining whether intravesical instillation effects vary according to individual characteristics, including age, sex, ethnicity, and tumor grade. Therefore, further large-scale, multicenter, prospective trials are needed to clarify these findings. Furthermore, causative genetic mutations of UUT-UC should be identified by whole-exome sequencing or whole-genome sequencing to identify pathogenicity factors. Drugs specific for pathogenic factors could be developed to move toward precision medicine. Multidisciplinary collaboration between pharmacology and molecular biology is needed to drive this process.

5. Conclusions

A maintenance schedule of intravesical instillation effectively prevents the recurrence of bladder cancer after RNU and improves the overall survival of UUT-UC patients. Further large, prospective studies are needed to verify its value. Compared with other chemotherapy regimens, THP may be a promising drug with favorable efficacy to prevent bladder recurrence. As the included studies had a moderate risk of bias, the conclusions of the network meta-analysis should be applied cautiously.

Data Availability

Data are available upon request to the corresponding author.

Conflicts of Interest

All authors declare that there are no conflicts in this study.

Authors’ Contributions

ZYL, XSS, CZ, BF, and QLT contributed to the study concept and design. Literature retrieval was carried out by MS and YZW. Extraction and summary of data were carried out by YTW, ZL, and XD. Statistical analysis was performed by BF, QLT, MS, and YZW. YCW, LRZ, TYC, SSC, and YT collected clinical data. BF and QLT wrote the manuscript. ZYL, XSS, and CZ reviewed the manuscript. All authors read and approved the final manuscript. Bo Fan, Qiliang Teng, Min Sun, and Yingzi Wang contributed equally to this work.
Acknowledgments

The present study was supported by grants from the National Natural Science Foundation of China (Grant nos. 31800787, 81772739, and 11872146), the United Fund of the Second Hospital of Dalian Medical University and Dalian Institute of Chemical Physics, Chinese Academy of Sciences (UF-QN-202004), the Dalian High-Level Talents Innovation Support Program (Grant no.2019RQ014), the Young Reserve Talent Project of the Second Hospital of Dalian Medical University (Grant no. dy2yhbrc202010), and “1+X” program for Clinical Competency enhancement—Interdisciplinary Innovation Project of the Second Hospital of Dalian Medical University (Grant no. 2022CXKXYB15).

Supplementary Materials

Supplementary Table 1: PRISMA checklist. Supplementary Table 2: main characteristics of twenty studies included in the meta-analysis. Supplementary Table 3: patient characteristics from eligible studies. (Supplementary Materials)

References

[1] F. A. Yafi, G. Novara, S. F. Shariat et al., “Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy,” BJU International, vol. 110, no. 2b, pp. E7–E13, 2012.
[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
[3] M. Roupôr, M. Babjuk, E. Compérat et al., “European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update,” European Urology, vol. 68, no. 5, pp. 868–879, 2015.
[4] M. Miyake, Y. Tatsumi, K. Fujimoto et al., “Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study,” Japanese Journal of Clinical Oncology, vol. 46, pp. 1148–1155, 2016.
[5] G. A. Brown, J. E. Busby, C. G. Wood et al., “Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm,” BJU International, vol. 98, no. 6, pp. 1176–1180, 2006.
[6] M. Roupôr, M. Babjuk, E. Compérat et al., “European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update,” European Urology, vol. 73, no. 1, pp. 111–122, 2018.
[7] V. Margulis, S. F. Shariat, S. F. Matin et al., “Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration,” Cancer, vol. 115, no. 6, pp. 1224–1233, 2009.
[8] R. Zigeuner and K. Pummer, “Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors,” European Urology, vol. 53, no. 4, pp. 720–731, 2008.
[9] Y. Miyazaki, T. Kosaka, S. Mikami et al., “The prognostic significance of vaso乙肝in-1 expression in patients with upper urinary tract urothelial carcinoma,” Clinical Cancer Research, vol. 18, no. 15, pp. 4145–4153, 2012.
[10] T. Doeveren, M. Mark, P. J. Leeuwen, J. L. Boormans, and K. K. A. Aeb, “Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017,” BJU International, vol. 128, no. 3, pp. 343–351, 2021.
[11] Q. Wang, T. Zhang, J. Wu et al., “Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China,” BMC Urology, vol. 19, no. 1, p. 24, 2019.
[12] M. Nishikawa, H. Miyake, and M. Fujisawa, “De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy,” Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 9, 2016.
[13] M. D. Azémar, E. Comperat, F. Richard, O. Cussenot, and M. Roupôr, “Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance,” Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 2, pp. 130–136, 2011.
[14] J. Krogh, E. Kvist, and B. Rye, “ Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences,” British Journal of Urology, vol. 67, no. 1, pp. 32–36, 1991.
[15] W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou, and C. H. Huang, “Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy,” The Journal of Urology, vol. 183, no. 1, pp. 56–61, 2010.
[16] Y. Matsui, N. Utsunomiya, K. Ichioka et al., “Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract,” Urology, vol. 65, no. 2, pp. 279–283, 2005.
[17] W. W. Huang, H. Y. Huang, A. C. Liao et al., “Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection,” Pathology International, vol. 59, no. 9, pp. 642–649, 2009.
[18] T. O’Brien, E. Ray, R. Singh, B. Coker, and R. Beard, “Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial),” European Urology, vol. 60, no. 4, pp. 703–710, 2011.
[19] E. i. Takaoka, S. Hinotsu, A. Joraku et al., “Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study,” International Journal of Urology, vol. 17, no. 7, pp. 623–628, 2010.
[20] M. Mullerad, P. Russo, D. Gelijian et al., “Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma,” The Journal of Urology, vol. 172, pp. 2177–2181, 2004.
[21] N. Sakamoto, S. Naito, J. Kumaawata et al., “Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumours following surgery for upper urinary tract tumors: a prospective randomized study,” International Journal of Urology, vol. 8, no. 5, pp. 212–216, 2001.
[22] T. Kudo, F. Motomura, F. Saitho, T. Kogawa, and T. Suzuki, “Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma,” Japanese Journal of Urology, vol. 81, no. 12, pp. 1857–1860, 1990.
[23] A. Ito, I. Shintaku, M. Satoh et al., “Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial,” Journal of Clinical Oncology, vol. 31, no. 11, pp. 1422–1427, 2013.

[24] T. R. Döbé, G. Califano, F. C. von Rundstedt et al., “Post-operative chemotherapy bladder instillation after radical nephroureterectomy: results of a European survey from the Young academic urologist urothelial cancer group,” European Urology Open Science, vol. 22, pp. 45–50, 2020.

[25] G. Salanti, “Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool,” Research Synthesis Methods, vol. 3, no. 2, pp. 80–97, 2012.

[26] S. Dias, N. J. Welton, D. M. Caldwell, and A. E. Ades, “Checking consistency in mixed treatment comparison meta-analysis,” Statistics in Medicine, vol. 29, no. 7-8, pp. 932–944, 2010.

[27] R. D. Riley, J. P. T. Higgins, and J. J. Deeks, “Interpretation of random effects meta-analyses,” BMJ (Clinical Research edition), vol. 342, p. d549, 2011.

[28] U. Krahn, H. Binder, and J. König, “A graphical tool for locating inconsistency in network meta-analyses,” BMC Medical Research Methodology, vol. 13, no. 1, p. 35, 2013.

[29] J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity,” Statistics in Medicine, vol. 26, no. 25, pp. 4544–4562, 2007.

[30] M. Rouprêt, O. Traxer, M. Tligui et al., “Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection,” European Urology, vol. 51, no. 3, pp. 709–714, 2007.

[31] M. Racioppi, A. D’Addessi, A. Alcini, A. Destito, and E. Alcini, “Clinical review of 100 consecutive surgically treated patients with upper urinary tract transitional tumours,” BJU International, vol. 80, no. 5, pp. 707–711, 1997.

[32] T. R. Hatch, T. R. Hefty, and J. M. Barry, “Time-related recurrence rates in patients with upper tract transitional cell carcinoma,” The Journal of Urology, vol. 140, no. 1, pp. 40–41, 1988.

[33] J. D. Raman, C. K. Ng, S. A. Boorjian, E. D. Vaughan Jr., R. E. Sosa, and D. S. Scherr, “Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology,” BJU International, vol. 96, no. 7, pp. 1031–1035, 2005.

[34] M. Muntener, M. E. Nielsen, F. R. Romero et al., “Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma,” European Urology, vol. 51, no. 6, pp. 1639–1644, 2007.

[35] A. Ito, I. Shintaku, M. Satoh et al., “Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial,” Japanese Journal of Clinical Oncology, vol. 43, no. 11, pp. 1139–1144, 2013.

[36] S. Yamashita, A. Ito, K. Mitsuzuka et al., “Clinical implications of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma,” International Journal of Urology, vol. 23, no. 5, pp. 378–384, 2016.

[37] A. M. Harraz, M. El-Shabrawy, A. R. El-Nahas, H. El-Kappany, and Y. Osman, “Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a randomized clinical trial,” Clinical Genitourinary Cancer, vol. 17, no. 6, pp. e1108–e1115, 2019.

[38] Y. Huang, J. Chen, Z. Liu et al., “A comparison of different prophylactic intravesical chemotherapy regimens for bladder cancer recurrence after nephroureterectomy for primary upper tract urothelial carcinomas: a retrospective 2-center study,” Technology in Cancer Research and Treatment, vol. 18, Article ID 15330381984448, 2019.

[39] E. Pieras, G. Frontera, X. Ruiz, A. Vicens, M. Ozonas, and P. Pizà, “Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma,” BJU International, vol. 106, no. 9, pp. 1319–1323, 2010.

[40] C. H. Lee, J. Y. Ku, C. W. Jeong et al., “Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis,” Clinical Genitourinary Cancer, vol. 15, pp. e1055–e1061, 2017.

[41] H. H. Sung, H. G. Jeon, D. H. Han et al., “Diagnostic ureterorenoscopy is associated with increased intravesical recurrence following radical nephroureterectomy in upper tract urothelial carcinoma,” PLoS One, vol. 10, no. 11, Article ID e0139976, 2015.

[42] V. Izol, M. Deger, E. Ozden et al., “The effect of diagnostic ureterorenoscopy on intravesical recurrence in patients undergoing nephroureterectomy for primary upper tract urinary carcinoma,” Urologia Internationalis, vol. 105, pp. 291–297, 2020.

[43] Y. Huang, J. Wei, Y. Fang et al., “Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma,” Cancer Management and Research, vol. 10, pp. 6997–7011, 2018.

[44] X. Long, X. Yu, Y. Li et al., “Epidermal growth factor receptor and ki-67 as predictive biomarkers identify patients who will Be more sensitive to intravesical instillations for the prevention of bladder cancer recurrence after radical nephroureterectomy,” PLoS One, vol. 11, Article ID e0166884, 2016.

[45] D. Fang, X. S. Li, G. Y. Xiong, L. Yao, Z. S. He, and L. Q. Zhou, “Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis,” Urologia Internationalis, vol. 91, no. 3, pp. 291–296, 2013.

[46] H. Yuan, X. Mao, Y. Bai et al., “The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis,” Journal of Chemotherapy, vol. 27, no. 4, pp. 195–200, 2015.

[47] P. Wu, G. Zhu, D. Wei et al., “Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis,” Journal of U.B.U.ON, Official Journal of the Balkan Union of Oncology, vol. 20, pp. 1229–1238, 2015.

[48] D. Pode, Y. Alon, A. T. Horowitz, I. Vlodavsky, and S. Biran, “The mechanism of human bladder tumor implantation in an in vitro model,” The Journal of Urology, vol. 136, no. 2, pp. 482–486, 1986.
carcinoma,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD013160, 2019.

[50] A. Gulamhusein, P. Silva, D. Cullen et al., “Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy,” BJU International, vol. 126, no. 6, pp. 739–744, 2020.

[51] J. A. Thomsen, H. Nielsen Dominiak, M. S. Lindgren, and J. B. Jensen, “Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients,” Scandinavian Journal of Urology, vol. 55, no. 4, pp. 281–286, 2021.

[52] H. Koga, M. Kuroda, S. Kudo et al., “Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder,” International Journal of Urology, vol. 12, no. 2, pp. 145–151, 2005.

[53] Y. Freifeld, R. Ghandour, N. Singla et al., “Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy,” Urologic Oncology: Seminars and Original Investigations, vol. 38, no. 9, 2020.

[54] B. Noennig, S. Bozorgmehri, R. Terry, B. Otto, L. M. Su, and P. L. Crispen, “Evaluation of intraoperative versus postoperative adjuvant mitomycin C with nephroureterectomy for urothelial carcinoma of the upper urinary tract,” Bladder Cancer, vol. 4, pp. 389–394, 2018.

[55] M. A. Moriarty, M. A. Uhlman, M. T. Bing et al., “Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy,” BMC Urology, vol. 15, no. 1, p. 45, 2015.